Clinique de La Sauvegarde

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer7 trials
• Colorectal cancer5 trials
• Bladder cancer2 trials
• Liver and biliary tract cancer2 trials
• Obesity2 trials
• Prostate cancer2 trials
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Osteoarthritis1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 310 trials
• Phase 25 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Recruiting12 trials
• Active, not recruiting6 trials
• Completed4 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• UNICANCER7 trials
• GCS Ramsay Santé pour l'Enseignement et la Recherche3 trials
• Federation Francophone de Cancerologie Digestive2 trials
• Assistance Publique Hopitaux De Paris1 trial
• Association Francaise d'Urologie1 trial
• and 11 more

Running trials

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· UNICANCER· Source

• Recruiting

  Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)

  NCT07449520· IHU Strasbourg· Source

  Contact: Marie-Cécile BLANCHET

• Recruiting

  Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

  NCT06680596· Phase 2· UNICANCER· Source

• Recruiting

  Evaluation of the Impact of Pilonidal Cyst Recurrence on Quality of Life in Patients Previously Treated With Conventional Surgery or Laser Therapy

  NCT07194161· GCS Ramsay Santé pour l'Enseignement et la Recherche· Source

  Contact: Benjamin Dr DARNIS

• Recruiting

  Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy

  NCT06532422· GCS Ramsay Santé pour l'Enseignement et la Recherche· Source

  Contact: Arnaud MD BALDINI

• Recruiting

  FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage

  NCT05168839· Phase 4· Centre Hospitalier Regional Universitaire· Source

• Recruiting

  A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

  2023-505660-11-00· Phase 3· Transthera Sciences (Nanjing) Inc.· Source

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  Outpatient Laparoscopic Radical Prostatectomy

  NCT05975775· GCS Ramsay Santé pour l'Enseignement et la Recherche· Source

  Contact: Arnaud BALDINI, MD

• Recruiting

  AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

  NCT05002556· Association Francaise d'Urologie· Source

  Contact: Emmanuel Deligne

• Recruiting

  Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

  NCT05706779· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)

  NCT04167007· Phase 2/3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

  NCT03819101· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Completed

  IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

  NCT02967289· Phase 3· UNICANCER· Source

• Completed

  PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

  NCT03079011· Phase 3· UNICANCER· Source

• Active, not recruiting

  Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

  NCT02505750· Phase 3· Centre Antoine Lacassagne· Source

• Active, not recruiting

  PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older

  NCT02355379· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Active, not recruiting

  Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

  NCT01805271· Phase 3· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Obesity2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· UNICANCER· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Unicancer· Source

• Completed

  Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2)

  NCT05978180· Labrha· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source